Premium
Sphingosine 1‐phosphate and its type 1 G protein‐coupled receptor: trophic support and functional regulation of T Lymphocytes
Author(s) -
Goetzl Edward J.,
Gräler Markus H.
Publication year - 2004
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.1103567
Subject(s) - biology , g protein coupled receptor , microbiology and biotechnology , immune system , homing (biology) , receptor , sphingosine 1 phosphate , immunology , t cell , sphingosine , signal transduction , biochemistry , ecology
The lysophospholipid (LPL) growth factors sphingosine 1‐phosphate (S1P) and lysophosphatidic acid (LPA) are generated by macrophages, dendritic cells, mast cells, and platelets, which leads to lymph and plasma concentrations of 0.1–1 μM. Distinctive profiles of G protein‐coupled receptors (GPCRs) for S1P and LPA are expressed by each type of immune cell and are regulated by cellular activation. At 1–100 nM, S1P signals T cells through their principal S1P 1 GPCRs with consequent protection from apoptosis, enhancement of chemotaxis, and facilitation of optimal regulatory activity of CD4 + 25 + T cells. At 0.3–3 μM, S1P inhibits T cell chemotaxis and to a lesser extent other functions. These S1P–S1P 1 GPCR signals suppress homing of blood and spleen T cells to secondary lymphoid tissues. S1P 1 GPCR antagonists evoke lymphopenia by permitting blood T cells to enter lymph nodes and blocking S1P 1 GPCR‐dependent T cell efflux from lymph nodes. Inversely, there is a decrease in lymphoid tissue traffic of T cells in transgenic mice, which overexpress lymphocyte S1P 1 GPCRs. The immunotherapeutic activity of S1P 1 GPCR antagonists, which limits T cell access to organ grafts and autoimmune antigens, does not reduce other functional capabilities of T cells. LPLs and their GPCRs thus constitute an immunoregulatory system of sufficient prominence for pharmacological targeting in transplantation, autoimmunity, and immunodeficiency.